Dr Venkat Reddy

Dr. Venkat Reddy is an Associate Professor at University College London (UCL) and an Honorary Consultant Rheumatologist at University College Hospital (UCH)  and holds the distinction of being the Division of Medicine Excellence Fellow in Rheumatology and Inflammation. His clinical and academic career is defined by a strong focus on complex immune-mediated diseases, translational research, and a commitment to medical education.

Dr. Reddy completed his medical qualifications with an MBBS and MRCP, followed by specialist training in rheumatology and general medicine through the London Deanery in 2011. He went on to earn a PhD from UCL, conducting pivotal research on why certain individuals with lupus and rheumatoid arthritis respond less effectively to B-cell targeting therapy with Rituximab. His work also explored the potential of Obinutuzumab, a newer biologic treatment, which may offer more efficient B-cell targeting and improved outcomes for these conditions. This work influenced treatment of real clinic lupus patients at specialist centres, such as UCH, around the world. 

At UCH/UCL, Dr. Reddy is part of a world-class lupus centre of excellence, where he treats a wide range of autoimmune and rheumatological conditions. These include rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, lupus (systemic lupus erythematosus), polymyalgia rheumatica, myositis, osteoarthritis, Sjogren’s syndrome, vasculitis, gout, osteoporosis, chronic fatigue, and a variety of soft tissue and musculoskeletal pain disorders.

With a background in general medicine, Dr. Reddy is particularly skilled in recognising and managing the complex medical issues that often accompany rheumatic disease. He believes in a holistic, lifestyle-centred approach to care, emphasising stress management, sleep hygiene, physical activity, and nutrition as key components in managing chronic conditions and improving fatigue.

His research continues to focus on optimising B-cell targeted therapies and advancing treatments for autoimmune diseases such as lupus and rheumatoid arthritis. Dr. Reddy collaborates with colleagues at UCH/UCL, researchers at the University of Southampton, and industry partners such as Roche Glycart in Basel. His work has contributed to the development of Obinutuzumab and helped initiate a multinational Phase I trial exploring novel T-cell engaging therapies for lupus.

Beyond clinical and research duties, Dr. Reddy works closely with adolescent rheumatology teams and is actively investigating how inflammation behaves across the human lifespan—both in health and in disease. He is passionate about mentoring the next generation of clinicians and scientists and was nominated for the Division of Medicine Teaching Excellence Award in 2024 in recognition of his dedication to teaching and professional development.